Symetis and Boston Scientific reach USD 435 million purchase agreement
<ul>
<li>Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment</li>
</ul>
<ul>
<li>Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease</li>
</ul>
<ul>
<li>Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions</li>
</ul>
<ul>
<li>Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted</li>
</ul>
<li>Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment</li>
</ul>
<ul>
<li>Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease</li>
</ul>
<ul>
<li>Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions</li>
</ul>
<ul>
<li>Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted</li>
</ul>
- 30.03.2017, 14:06
- Kategoria: Nauka i technologie
- Źródło: APA-OTS